2012
DOI: 10.1016/j.bbrc.2012.03.067
|View full text |Cite
|
Sign up to set email alerts
|

Expression and immunogenicity of novel subunit enterovirus 71 VP1 antigens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
11
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(12 citation statements)
references
References 23 publications
1
11
0
Order By: Relevance
“…1C). VP1, an outer surface capsid protein of EV71, is reportedly involved in virus infectivity (68) and immunogenicity (69,70). VP1 has been shown to interact with the cell surface receptors SCARB2 and PSGL-1 (71,72) and with the binding molecules lactoferrin and annexin IIA (10,73).…”
Section: Figmentioning
confidence: 99%
“…1C). VP1, an outer surface capsid protein of EV71, is reportedly involved in virus infectivity (68) and immunogenicity (69,70). VP1 has been shown to interact with the cell surface receptors SCARB2 and PSGL-1 (71,72) and with the binding molecules lactoferrin and annexin IIA (10,73).…”
Section: Figmentioning
confidence: 99%
“…The four structural proteins are the major Ags of EV71 and have thus been the focus of vaccine development and applied as the main effective constituents in vaccine effectiveness evaluations (13,14). In particular, VP1 is highly exposed, as well as considered the main target of neutralizing Abs, and has thus been broadly used for subunit vaccine development (15)(16)(17). The lower prevalence of neutralizing Abs accompanied by higher transmission rates in children and infants indicates that neutralizing Abs are important for the prevention of EV71 infection (8,18).…”
mentioning
confidence: 99%
“…In our previous research, a pilot antigen engineering study was conducted to explore novel VP1 designs to improve expression and immunogenicity of VP1 antigen [ 21 ] . Five codon-optimized VP1 DNA vaccines, including wt-VP1, tPA-VP1, tPA-VP1-dimer (VP1-d), tPA-VP1-hFc (VP1-hFc) and tPA-VP1-mFc (VP1-mFc), were constructed and tested for in vitro expression and in vivo immunogenicity.…”
Section: Introductionmentioning
confidence: 99%
“…In this study, we investigated possible factors that could affect the expression, secretion, and immuno- genicity of VP1 DNA vaccines. In our previous study, we showed that VP1-mFc expressed at significantly lower levels and failed to mount an effective immune response [ 21 ] . In subsequent experiments, an EV71 VP1 monoclonal antibody raised in mice was investigated to further identify the optimal configuration of VP1.…”
Section: Introductionmentioning
confidence: 99%